Obesity creates a graded dose-response relationship with atrial fibrillation incidence and recurrence, driving a specific form of atrial cardiomyopathy through multiple interconnected mechanisms including structural fibrosis, epicardial fat expansion, chronic inflammation, and autonomic nervous system imbalance. The pathophysiology extends beyond simple mechanical effects to include dysregulated adipose tissue signaling and metabolic disturbances that actively promote arrhythmia initiation.
This mechanistic understanding opens compelling therapeutic avenues beyond traditional rhythm management. The evidence for sustained weight loss reducing AF burden aligns with emerging data on GLP-1 receptor agonists and bariatric surgery as potentially disease-modifying interventions rather than merely symptomatic treatments. This represents a paradigm shift toward addressing root metabolic causes rather than downstream electrical consequences. However, the field still lacks definitive randomized trials proving direct atrial benefits of metabolic therapies, and the optimal timing and patient selection criteria remain unclear. The obesity-AF connection exemplifies how metabolic health increasingly intersects with cardiovascular disease prevention, suggesting integrated weight management may become standard care for AF patients.